IL289436A - Methods for treating ocular diseases - Google Patents

Methods for treating ocular diseases

Info

Publication number
IL289436A
IL289436A IL289436A IL28943621A IL289436A IL 289436 A IL289436 A IL 289436A IL 289436 A IL289436 A IL 289436A IL 28943621 A IL28943621 A IL 28943621A IL 289436 A IL289436 A IL 289436A
Authority
IL
Israel
Prior art keywords
methods
eye diseases
treating eye
treating
diseases
Prior art date
Application number
IL289436A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL289436A publication Critical patent/IL289436A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL289436A 2019-09-13 2021-12-27 Methods for treating ocular diseases IL289436A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899892P 2019-09-13 2019-09-13
US202062971405P 2020-02-07 2020-02-07
PCT/IB2020/058459 WO2021048806A1 (en) 2019-09-13 2020-09-11 Methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
IL289436A true IL289436A (en) 2022-02-01

Family

ID=72521675

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289436A IL289436A (en) 2019-09-13 2021-12-27 Methods for treating ocular diseases

Country Status (11)

Country Link
US (1) US12649781B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028128A1 (cg-RX-API-DMAC7.html)
JP (2) JP7828274B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062279A (cg-RX-API-DMAC7.html)
CN (1) CN114375201A (cg-RX-API-DMAC7.html)
AU (1) AU2020347575A1 (cg-RX-API-DMAC7.html)
CA (1) CA3149706A1 (cg-RX-API-DMAC7.html)
IL (1) IL289436A (cg-RX-API-DMAC7.html)
MX (1) MX2022003101A (cg-RX-API-DMAC7.html)
TW (1) TW202116802A (cg-RX-API-DMAC7.html)
WO (1) WO2021048806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202337496A (zh) * 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
US20160220675A1 (en) 2013-09-11 2016-08-04 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
MX2020009140A (es) 2018-03-16 2020-09-28 Novartis Ag Metodos para el tratamiento de enfermedades oculares.
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases

Also Published As

Publication number Publication date
CN114375201A (zh) 2022-04-19
US12649781B2 (en) 2026-06-09
US20240052024A1 (en) 2024-02-15
EP4028128A1 (en) 2022-07-20
TW202116802A (zh) 2021-05-01
MX2022003101A (es) 2022-04-06
JP2022547537A (ja) 2022-11-14
CA3149706A1 (en) 2021-03-18
AU2020347575A1 (en) 2022-03-17
KR20220062279A (ko) 2022-05-16
JP2026072102A (ja) 2026-04-30
WO2021048806A1 (en) 2021-03-18
JP7828274B2 (ja) 2026-03-11

Similar Documents

Publication Publication Date Title
IL277333A (en) Methods for treating eye diseases
IL283561B (en) Methods for treating ocular diseases
IL282794A (en) Therapeutic methods
IL277190A (en) Methods of treating HPV-related diseases
IL269174A (en) Methods for treating complement-mediated diseases and disorders
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3347368A4 (en) COMPOUNDS AND FORMULATIONS FOR THE TREATMENT OF EYE DISEASES
IL261935A (en) Methods of treatment of cholestatic diseases
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
SG10202102156YA (en) Ophthalmic lenses for treating myopia
IL291362A (en) Treatment of syngap1 encephalopathy
IL272081A (en) Photodynamic therapy method for skin disorders
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
IL281736A (en) Methods of treating myeloproliferative disorders
EP3746178A4 (en) CONTROLLABLE EYEPIECE PHOTOTHERAPY
EP3751048A4 (en) FIBER TREATMENT AGENTS
IL257764B (en) Methods for treatment of diseases
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
IL292502A (en) Therapeutic methods using vadadustat
PT3952858T (pt) Método de tratamento de tumores
IL269698B (en) Methods for preventing or treating eye diseases
IL281343A (en) Methods for treating pancreatitis
IL281589A (en) Methods of treating myeloproliferative disorders
IL265596A (en) Methods for treating ocular disease using inhibitors of csf-1r
IL281839A (en) Treatment methods